PMID- 28809468
OWN - NLM
STAT- MEDLINE
DCOM- 20190115
LR  - 20210109
IS  - 1944-8252 (Electronic)
IS  - 1944-8244 (Linking)
VI  - 9
IP  - 35
DP  - 2017 Sep 6
TI  - Construction of a Supramolecular Drug-Drug Delivery System for Non-Small-Cell 
      Lung Cancer Therapy.
PG  - 29505-29514
LID - 10.1021/acsami.7b07565 [doi]
AB  - Nanoscale drug delivery systems (DDSs) are generally considered to be an 
      effective alternative to small molecular chemotherapeutics due to improved 
      accumulation in the tumor site and enhanced retention in blood. Nevertheless, 
      most DDSs have low loading efficiency or even pose a high threat to normal organs 
      from severe side effects. Ideally, a supramolecular drug-drug delivery system 
      (SDDDS) composed of pure drugs via supramolecular interaction provides a hopeful 
      approach for cancer treatment. Herein we propose a facile method to construct 
      SDDDS via coassembly of gefitinib (GEF) and tripeptide tyroservatide (YSV), two 
      kinds of chemotherapeutic pharmaceuticals for non-small-cell lung cancer (NSCLC) 
      via multiple intermolecular interactions, including hydrogen bonding and pi-pi 
      stacking. As shown through transmission electron microscopy (TEM) and dynamic 
      light scattering (DLS), GEF and YSV self-assemble into nanoparticles with regular 
      morphology and uniform size, which facilitates the delivery of both drugs. In 
      vitro studies demonstrate that the SDDDS is much more efficient in entering 
      cancer cells and inhibiting the proliferation of cancer cells compared with 
      single GEF, YSV, or GEF/YSV drug mixture. In vivo experiments show that the SDDDS 
      can selectively accumulate in tumor tissue, resulting in much better drug 
      efficacy without evident side effects. Considering the advantages of the SDDDS, 
      we believe this strategy provides a promising route for enhanced anticancer 
      therapy in nanomedicine.
FAU - Zhang, Zhihao
AU  - Zhang Z
AD  - School of Chemistry and Chemical Engineering, State Key Laboratory of Metal 
      Matrix Composites, Shanghai Jiao Tong University , 800 Dongchuan Road, Shanghai 
      200240, People's Republic of China.
FAU - Shi, Leilei
AU  - Shi L
AD  - School of Chemistry and Chemical Engineering, State Key Laboratory of Metal 
      Matrix Composites, Shanghai Jiao Tong University , 800 Dongchuan Road, Shanghai 
      200240, People's Republic of China.
FAU - Wu, Chenwei
AU  - Wu C
AD  - School of Chemistry and Chemical Engineering, State Key Laboratory of Metal 
      Matrix Composites, Shanghai Jiao Tong University , 800 Dongchuan Road, Shanghai 
      200240, People's Republic of China.
FAU - Su, Yue
AU  - Su Y
AD  - School of Chemistry and Chemical Engineering, State Key Laboratory of Metal 
      Matrix Composites, Shanghai Jiao Tong University , 800 Dongchuan Road, Shanghai 
      200240, People's Republic of China.
FAU - Qian, Jiwen
AU  - Qian J
AD  - School of Chemistry and Chemical Engineering, State Key Laboratory of Metal 
      Matrix Composites, Shanghai Jiao Tong University , 800 Dongchuan Road, Shanghai 
      200240, People's Republic of China.
FAU - Deng, Hongping
AU  - Deng H
AD  - School of Chemistry and Chemical Engineering, State Key Laboratory of Metal 
      Matrix Composites, Shanghai Jiao Tong University , 800 Dongchuan Road, Shanghai 
      200240, People's Republic of China.
FAU - Zhu, Xinyuan
AU  - Zhu X
AUID- ORCID: 0000-0002-2891-837X
AD  - School of Chemistry and Chemical Engineering, State Key Laboratory of Metal 
      Matrix Composites, Shanghai Jiao Tong University , 800 Dongchuan Road, Shanghai 
      200240, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20170825
PL  - United States
TA  - ACS Appl Mater Interfaces
JT  - ACS applied materials & interfaces
JID - 101504991
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents
MH  - Carcinoma, Non-Small-Cell Lung
MH  - Cell Line, Tumor
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Lung Neoplasms
MH  - Nanoparticles
OTO - NOTNLM
OT  - chemotherapy
OT  - drug delivery
OT  - nanoparticles
OT  - non-small-cell lung cancer
OT  - self-assembly
EDAT- 2017/08/16 06:00
MHDA- 2019/01/16 06:00
CRDT- 2017/08/16 06:00
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2019/01/16 06:00 [medline]
PHST- 2017/08/16 06:00 [entrez]
AID - 10.1021/acsami.7b07565 [doi]
PST - ppublish
SO  - ACS Appl Mater Interfaces. 2017 Sep 6;9(35):29505-29514. doi: 
      10.1021/acsami.7b07565. Epub 2017 Aug 25.